Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma Treatment with the triplet regimen of ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
CHICAGO -- A second-line triplet regimen involving the novel intravenous drug gedatolisib significantly reduced the risk of progression or death in PIK3CA-mutant hormone receptor (HR)-positive breast ...
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting 33% ORR and 67% disease control observed with ...
Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results